Dapagliflozin · DAPAGLIFLOZIN 10 mg/1 · Tablet, Film Coated · Oral · Apotex Corp.
NDC 60505-4912-03 · 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC · ANDA · View full market →
20 companies supply this market — deep enough that no single failure threatens the supply. The brand (Farxiga) runs $12.08 per unit — 62× more. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | PC | Oct 3, 2026 |
| exclusivity | PC | Oct 3, 2026 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | DAPAGLIFLOZIN PROPANEDIOL 10 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| AstraZeneca Pharmaceuticals LP | DAPAGLIFLOZIN PROPANEDIOL 5 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| AstraZeneca Pharmaceuticals LP | DAPAGLIFLOZIN PROPANEDIOL 10 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| A-S Medication Solutions | DAPAGLIFLOZIN 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| A-S Medication Solutions | DAPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Inc. | DAPAGLIFLOZIN 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Inc. | DAPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Limited | DAPAGLIFLOZIN 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Limited | DAPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| ANI Pharmaceuticals, Inc. | DAPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| ANI Pharmaceuticals, Inc. | DAPAGLIFLOZIN 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Apotex Corp. | DAPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Apotex Corp. | DAPAGLIFLOZIN 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Ascend Laboratories, LLC | DAPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Ascend Laboratories, LLC | DAPAGLIFLOZIN 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AstraZeneca AB | DAPAGLIFLOZIN PROPANEDIOL 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AstraZeneca AB | DAPAGLIFLOZIN PROPANEDIOL 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | DAPAGLIFLOZIN 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | DAPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | DAPAGLIFLOZIN 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | DAPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Biocon Pharma Inc. | DAPAGLIFLOZIN 2,3-BUTANEDIOL MONOHYDRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Biocon Pharma Inc. | DAPAGLIFLOZIN 2,3-BUTANEDIOL MONOHYDRATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | DAPAGLIFLOZIN PROPANEDIOL 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Cipla USA Inc. | DAPAGLIFLOZIN PROPANEDIOL 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Cipla USA Inc. | DAPAGLIFLOZIN PROPANEDIOL 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| IPR Pharmaceuticals, Inc | DAPAGLIFLOZIN PROPANEDIOL 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| IPR Pharmaceuticals, Inc | DAPAGLIFLOZIN PROPANEDIOL 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | DAPAGLIFLOZIN 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | DAPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Prasco Laboratories | DAPAGLIFLOZIN PROPANEDIOL 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Prasco Laboratories | DAPAGLIFLOZIN PROPANEDIOL 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Remedyrepack Inc. | DAPAGLIFLOZIN PROPANEDIOL 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sandoz Inc | DAPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sandoz Inc | DAPAGLIFLOZIN 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals USA, Inc. | DAPAGLIFLOZIN 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals USA, Inc. | DAPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals, Inc. | DAPAGLIFLOZIN 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals, Inc. | DAPAGLIFLOZIN 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| A-S Medication Solutions | DAPAGLIFLOZIN PROPANEDIOL 5 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Dapagliflozin — NDC 60505-4912-03," retrieved September 3, 2026, https://drugdashboards.com/drug/60505491203.
Free to cite with attribution — see how the data is put together.